argenx SE ARGNF:Grey Market

RT Quote | Exchange | USD
Last | 01/10/22 EST
301.65UNCH (UNCH)
52 week range
273.94 - 343.50
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close301.65
  • 52 Week High343.50
  • 52 Week High Date01/05/22
  • 52 Week Low273.94
  • 52 Week Low Date11/22/21

Key Stats

  • Market Cap14,672.67M
  • Shares Out51.4M
  • 10 Day Average Volume93.5
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close301.65
  • 52 Week High343.50
  • 52 Week High Date01/05/22
  • 52 Week Low273.94
  • 52 Week Low Date11/22/21
  • Market Cap14,672.67M
  • Shares Out51.4M
  • 10 Day Average Volume93.5
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-7.96
  • P/E (TTM)-37.90
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor...
Peter Verhaeghe
Non-Executive Independent Chairman of the Board
Tim Van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Keith Woods
Chief Operating Officer
Karl Gubitz
Chief Financial Officer
Dirk Beeusaert
General Counsel
Address
Willemstraat 5
Breda
4811 AH
Netherlands